BR112017021583A2 - métodos para o tratamento de transtornos inflamatórios - Google Patents

métodos para o tratamento de transtornos inflamatórios

Info

Publication number
BR112017021583A2
BR112017021583A2 BR112017021583A BR112017021583A BR112017021583A2 BR 112017021583 A2 BR112017021583 A2 BR 112017021583A2 BR 112017021583 A BR112017021583 A BR 112017021583A BR 112017021583 A BR112017021583 A BR 112017021583A BR 112017021583 A2 BR112017021583 A2 BR 112017021583A2
Authority
BR
Brazil
Prior art keywords
methods
inflammatory disorders
treating inflammatory
formula
solvate
Prior art date
Application number
BR112017021583A
Other languages
English (en)
Inventor
Paul VANHOUTTE Frédéric
Albert Eleutherius Van 't Klooster Gerben
Tom Bert Paul Wigerinck Piet
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1506229.2A external-priority patent/GB201506229D0/en
Priority claimed from GBGB1506419.9A external-priority patent/GB201506419D0/en
Priority claimed from GBGB1507113.7A external-priority patent/GB201507113D0/en
Priority claimed from GBGB1513345.7A external-priority patent/GB201513345D0/en
Priority claimed from GBGB1513993.4A external-priority patent/GB201513993D0/en
Priority claimed from GBGB1521543.7A external-priority patent/GB201521543D0/en
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of BR112017021583A2 publication Critical patent/BR112017021583A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

a presente invenção descreve compostos de acordo com a fórmula i: ou um sal farmaceuticamente aceitável do mesmo ou um solvato ou o sal de um solvato do mesmo, composições farmacêuticas que compreendem os mesmos e métodos de tratamento usando os mesmos para uso no tratamento de condições inflamatórias através de administração do composto de acordo com fórmula i.
BR112017021583A 2015-04-13 2016-03-31 métodos para o tratamento de transtornos inflamatórios BR112017021583A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1506229.2A GB201506229D0 (en) 2015-04-13 2015-04-13 Methods For the Treatment Of Inflammatory Disorders
GBGB1506419.9A GB201506419D0 (en) 2015-04-15 2015-04-15 Methods for the treatment of inflammatory disorders
GBGB1507113.7A GB201507113D0 (en) 2015-04-27 2015-04-27 Methods for the treatment of inflammatory disorders
GBGB1513345.7A GB201513345D0 (en) 2015-07-29 2015-07-29 Methods for the treatment of Inflammatory disorders
GBGB1513993.4A GB201513993D0 (en) 2015-08-07 2015-08-07 Methods for the treatment of inflammatory disorders
GBGB1521543.7A GB201521543D0 (en) 2015-12-07 2015-12-07 Methods for the treatment of inflammatory disorders
PCT/EP2016/057104 WO2016165953A1 (en) 2015-04-13 2016-03-31 Methods for the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
BR112017021583A2 true BR112017021583A2 (pt) 2018-07-03

Family

ID=55650412

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017021583A BR112017021583A2 (pt) 2015-04-13 2016-03-31 métodos para o tratamento de transtornos inflamatórios

Country Status (12)

Country Link
US (1) US20180200257A1 (pt)
EP (1) EP3283078A1 (pt)
JP (1) JP2018511620A (pt)
KR (1) KR20170134750A (pt)
CN (1) CN107531694A (pt)
AU (1) AU2016248728A1 (pt)
BR (1) BR112017021583A2 (pt)
CA (1) CA2982630A1 (pt)
EA (1) EA201792264A1 (pt)
MX (1) MX2017013099A (pt)
SG (1) SG11201708181RA (pt)
WO (1) WO2016165953A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3043396A1 (en) 2016-11-10 2018-05-17 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
CN109111575B (zh) * 2018-05-23 2021-03-23 中山大学 一种金属-有机框架纳米颗粒的制备方法和应用
GB201808575D0 (en) * 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits
US20220016165A1 (en) * 2020-02-20 2022-01-20 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
EP4232146A1 (en) * 2020-10-22 2023-08-30 Biora Therapeutics, Inc. Methods of treating and predicting non-response to anti-tnf treatment in subjects with gastrointestinal tract diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
PL2863950T3 (pl) 2012-06-22 2019-02-28 Galapagos Nv Aminotriazolopirydyna do zastosowania w leczeniu zapalenia i jej kompozycje farmaceutyczne
GB201402071D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
WO2016165953A1 (en) 2016-10-20
CA2982630A1 (en) 2016-10-20
CN107531694A (zh) 2018-01-02
EA201792264A1 (ru) 2018-04-30
EP3283078A1 (en) 2018-02-21
KR20170134750A (ko) 2017-12-06
SG11201708181RA (en) 2017-11-29
JP2018511620A (ja) 2018-04-26
MX2017013099A (es) 2018-01-26
US20180200257A1 (en) 2018-07-19
AU2016248728A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
BR112018070602A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
BR112017011972A2 (pt) derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
BR112015024530A2 (pt) composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto
UY36112A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015020302A2 (pt) derivado de pirazol
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112015022041A2 (pt) derivados substituídos de 3-fenilpropilamina para o tratamento de doenças e distúrbios oftálmicas
BR112017002403A2 (pt) formas de cristais de inibidores de glutaminase
BR112017018872A2 (pt) combinação de um antagonista pd-1 e eribulina para tratamento de câncer
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
BR112016017317A2 (pt) composto, antagonista de trpa1, medicamento, e, uso de um composto
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial
TW201613578A (en) Pharmaceutical combinations
BR112017006002A2 (pt) compostos de imidazopiridazina e seu uso
BR112019005318A2 (pt) compostos de aza-indazol para uso em lesões no tendão e/ou ligamento
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
BR112021011325A2 (pt) Derivados de rapamicina
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
BR112018073553A2 (pt) medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]